2022 American Transplant Congress
Risk for Loss of Hepatitis B Surface Antibody or Hepatitis B Reactivation in Kidney Transplant Recipients Receiving Lymphocyte Depleting Induction
*Purpose: Although used in over 60% of kidney transplant recipients, the impact of lymphocyte depleting induction on hepatitis B surface antibody (HBsAb) and hepatitis B…2022 American Transplant Congress
Outcomes in Elderly Black Renal Transplant Recipients Receiving Basiliximab Induction and Early Steroid Withdrawal
University of Maryland Medical Center, Baltimore, MD
*Purpose: Black renal transplant recipients (RTR) carry a higher risk of rejection (BPAR) and graft loss due to immunologic and non-immunologic factors. Lymphocyte depleting induction…2021 American Transplant Congress
Single-Dose Basiliximab Induction Therapy in Low-Immunologic Risk Kidney Transplant Recipients
Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to examine the outcomes associated with single-dose basiliximab in low-immunologic risk kidney transplant recipients following a revision to…2021 American Transplant Congress
A Comparative Analysis of Kidney Allograft Outcomes in Steroid Use versus Steroid Discontinuation After Basiliximab Induction: Unos Data Base Study
*Purpose: Basiliximab is a monoclonal antibody produced by recombinant DNA technology used by many transplant centers in the U.S. as induction immunosuppression. When Basiliximab is…2020 American Transplant Congress
Comparison of Outcome Between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
Transplantation, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: For preventing immunological rejection after kidney transplantation, induction immunosuppressant agents such as basiliximab or rabbit anti-thymocyte globulin (r-ATG) are mostly used nowadays. We compared…2020 American Transplant Congress
Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System
*Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…2020 American Transplant Congress
The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients
Weill Cornell Medical Center, New York, NY
*Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…2020 American Transplant Congress
Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant
Wake Forest Baptist Health System, Winston Salem, NC
*Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is…2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…2019 American Transplant Congress
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
*Purpose: The aim of our study was to compare the outcomes one-year after renal transplant with a focus on opportunistic infections in patients who received…
American Transplant Congress abstracts